The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
Authors
Lallo, AliceFrese, Kristopher K
Morrow, C
Szczepaniak S
Gulati, Sakshi
Schenk, Maximilian W
Trapani, F
Simms, N
Galvin, Melanie
Brown, Stewart
Hodgkinson, Cassandra L
Priest, Lynsey
Hughes, A
Lai, Z
Cadogan, E
Khandelwal, Garima
Simpson, Kathryn L
Miller, Crispin J
Blackhall, Fiona H
O'Connor, M
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester InstituteIssue Date
2018-06-25
Metadata
Show full item recordAbstract
Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer, a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patient relevant models to interrogate novel therapies. Following our development of circulating tumour cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for small cell lung cancer.Citation
The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. 2018, Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-17-2805PubMed ID
29941481Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-17-2805
Scopus Count
Collections
Related articles
- Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
- Authors: Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L
- Issue date: 2018 Jun 28
- Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
- Authors: Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach JV, Wang J, Byers LA
- Issue date: 2017 Oct 15
- Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
- Authors: Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA
- Issue date: 2014 Oct 1
- Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
- Authors: Ha DH, Min A, Kim S, Jang H, Kim SH, Kim HJ, Ryu HS, Ku JL, Lee KH, Im SA
- Issue date: 2020 Jun 18
- The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
- Authors: Ma L, Bian X, Lin W
- Issue date: 2020 Oct 17